{"title":"Immune checkpoint inhibitors: Utilizing patient's own immunity to treat oral cancer.","authors":"Rashmi Gs Phulari, Bharvi Solanki","doi":"10.4103/jomfp.jomfp_327_22","DOIUrl":null,"url":null,"abstract":"<p><p>Head and Neck squamous cell carcinoma is an immunosuppressive state. HNSCC evades immune responses through multiple resistance mechanisms. Because of better understanding of interaction between tumour microenvironment and immune regulators, there is increasing interest in role of immunotherapy as a treatment modality of HNSCC. Many clinical trials have been performed using checkpoint inhibitors, as monotherapies and combination therapies. Immune checkpoint molecule, programmed cell death 1 (PD-1) has shown promising results as a treatment of Recurrent and Metastatic HNSCC. This review discusses immune checkpoint molecules, their functional mechanisms, role of immunotherapy as a monotherapies and combination therapy for better treatment and prognosis of HNSCC patients.</p>","PeriodicalId":38846,"journal":{"name":"Journal of Oral and Maxillofacial Pathology","volume":"28 4","pages":"641-650"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11819625/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral and Maxillofacial Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jomfp.jomfp_327_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Head and Neck squamous cell carcinoma is an immunosuppressive state. HNSCC evades immune responses through multiple resistance mechanisms. Because of better understanding of interaction between tumour microenvironment and immune regulators, there is increasing interest in role of immunotherapy as a treatment modality of HNSCC. Many clinical trials have been performed using checkpoint inhibitors, as monotherapies and combination therapies. Immune checkpoint molecule, programmed cell death 1 (PD-1) has shown promising results as a treatment of Recurrent and Metastatic HNSCC. This review discusses immune checkpoint molecules, their functional mechanisms, role of immunotherapy as a monotherapies and combination therapy for better treatment and prognosis of HNSCC patients.
期刊介绍：
The journal of Oral and Maxillofacial Pathology [ISSN:print-(0973-029X, online-1998-393X)] is a tri-annual journal published on behalf of “The Indian Association of Oral and Maxillofacial Pathologists” (IAOMP). The publication of JOMFP was started in the year 1993. The journal publishes papers on a wide spectrum of topics associated with the scope of Oral and Maxillofacial Pathology, also, ensuring scientific merit and quality. It is a comprehensive reading material for the professionals who want to upgrade their diagnostic skills in Oral Diseases; allows exposure to newer topics and methods of research in the Oral-facial Tissues and Pathology. New features allow an open minded thinking and approach to various pathologies. It also encourages authors to showcase quality work done by them and to compile relevant cases which are diagnostically challenging. The Journal takes pride in maintaining the quality of articles and photomicrographs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
